Celsion Corporation (NASDAQ:CLSN) announced initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer. In early studies, conducted at Duke University Medical Center, investigators report that ThermoDox® has demonstrated significant promise in treating this highly aggressive disease.
More...
Linear Mode
